Genomic and evolutionary portraits of disease relapse in acute myeloid leukemia

Abstract excerpt

Relapse in acute myeloid leukemia (AML) patients remains a clinical challenge. The majority of AML patients who receive induction treatment with combination chemotherapy achieve clinicopathologic remission. However, a significant proportion of these patients will relapse and succumb to chemoresistant disease [ 1 ]. The biological mechanisms that contribute to relapsed AML are yet to be fully deciphered. Previous...